S'abonner

Salvage radiotherapy with or without short-term hormone therapy for rising prostate-specific antigen concentration after radical prostatectomy (GETUG-AFU 16): a randomised, multicentre, open-label phase 3 trial - 07/06/16

Doi : 10.1016/S1470-2045(16)00111-X 
Christian Carrie, DrMD a, , Ali Hasbini, MD b, Guy de Laroche, MD c, Pierre Richaud, MD d, Stéphane Guerif, MD e, Igor Latorzeff, MD f, Stéphane Supiot, PhD g, h, Mathieu Bosset, MD i, Jean-Léon Lagrange, ProfPhD j, Véronique Beckendorf, MD k, François Lesaunier, MD l, Bernard Dubray, ProfPhD m, n, Jean-Philippe Wagner, MD o, Tan Dat N’Guyen, ProfMD p, Jean-Philippe Suchaud, MD q, Gilles Créhange, ProfPhD r, Nicolas Barbier, MD s, Muriel Habibian, MSc t, Céline Ferlay, MSc u, Philippe Fourneret, MD v, Alain Ruffion, ProfMD w, x, Sophie Dussart, MD u
a Department of Radiotherapy, Centre Léon Bérard, Lyon, France 
b Department of Radiotherapy, Clinique Armoricaine, Saint-Brieuc, France 
c Department of Radiotherapy, Institut de Cancérologie de la Loire, Saint Priest en Jarez, France 
d Department of Radiotherapy, Institut Bergonié, Bordeaux, France 
e Department of Radiotherapy, Centre Hospitalier Universitaire, Poitiers, France 
f Department of Radiotherapy, Groupe ONCORAD Garonne and Clinique Pasteur, Toulouse, France 
g Department of Radiotherapy, Institut de Cancérologie de l’Ouest René Gauducheau, Saint Herblain, University of Nantes, Nantes, France 
h INSERM UMR892, Nantes, France 
i Department of Radiotherapy, Centre Marie Curie, Valence, France 
j Department of Radiotherapy, Hôpital Henri Mondor, Créteil, France 
k Department of Radiotherapy, Institut de Cancérologie de Lorraine Alexis Vautrin, Nancy, France 
l Department of Radiotherapy, Centre François Baclesse, Caen, France 
m Radiation Oncology and Medical Physics, QuantIF LITIS (EA4108), Centre Henri Becquerel, Rouen, France 
n Rouen University Hospital, University of Rouen, Rouen, France 
o Department of Radiotherapy, Centre de Radiothérapie, Strasbourg, France 
p Department of Radiotherapy, Institut Jean Godinot, Reims, France 
q Department of Radiotherapy, Centre Hospitalier, Roanne, France 
r Department of Radiotherapy, Centre George-François Leclerc, Dijon, France 
s Department of Radiotherapy, Centre Catalan d’oncologie, Perpignan, France 
t R&D, Unicancer, Paris, France 
u Direction of Clinical Research and Innovation, Centre Léon Bérard, Lyon, France 
v Department of Radiotherapy, Centre Hospitalier Métropole Savoie, Chambéry, France 
w Department of Urology, Hôpital Lyon Sud, Pierre Bénite, Lyon, France 
x Cancer Research Centre of Lyon, INSERM 1052 CNRS 5286, Lyon 1 University, Lyon, France 

* Correspondence to: Dr Christian Carrie, Centre Léon Bérard, 28 Rue Laënnec, 69373 Lyon CEDEX 08, France Centre Léon Bérard 28 Rue Laënnec 69373 Lyon CEDEX 08 France

Summary

Background

How best to treat rising prostate-specific antigen (PSA) concentration after radical prostatectomy is an urgent clinical question. Salvage radiotherapy delays the need for more aggressive treatment such as long-term androgen suppression, but fewer than half of patients benefit from it. We aimed to establish the effect of adding short-term androgen suppression at the time of salvage radiotherapy on biochemical outcome and overall survival in men with rising PSA following radical prostatectomy.

Methods

This open-label, multicentre, phase 3, randomised controlled trial, was done in 43 French study centres. We enrolled men (aged ≥18 years) who had received previous treatment for a histologically confirmed adenocarcinoma of the prostate (but no previous androgen deprivation therapy or pelvic radiotherapy), and who had stage pT2, pT3, or pT4a (bladder neck involvement only) in patients who had rising PSA of 0·2 to less than 2·0 μg/L following radical prostatectomy, without evidence of clinical disease. Patients were randomly assigned (1:1) centrally via an interactive web response system to standard salvage radiotherapy (three-dimensional [3D] conformal radiotherapy or intensity modulated radiotherapy, of 66 Gy in 33 fractions 5 days a week for 7 weeks) or radiotherapy plus short-term androgen suppression using 10·8 mg goserelin by subcutaneous injection on the first day of irradiation and 3 months later. Randomisation was stratified using a permuted block method according to investigational site, radiotherapy modality, and prognosis. The primary endpoint was progression-free survival, analysed in the intention-to-treat population. This trial is registered with ClinicalTrials.gov, number NCT00423475.

Findings

Between Oct 19, 2006, and March 30, 2010, 743 patients were randomly assigned, 374 to radiotherapy alone and 369 to radiotherapy plus goserelin. Patients assigned to radiotherapy plus goserelin were significantly more likely than patients in the radiotherapy alone group to be free of biochemical progression or clinical progression at 5 years (80% [95% CI 75–84] vs 62% [57–67]; hazard ratio [HR] 0·50, 95% CI 0·38–0·66; p<0·0001). No additional late adverse events occurred in patients receiving short-term androgen suppression compared with those who received radiotherapy alone. The most frequently occuring acute adverse events related to goserelin were hot flushes, sweating, or both (30 [8%] of 366 patients had a grade 2 or worse event; 30 patients [8%] had hot flushes and five patients [1%] had sweating in the radiotherapy plus goserelin group vs none of 372 patients in the radiotherapy alone group). Three (8%) of 366 patients had grade 3 or worse hot flushes and one patient had grade 3 or worse sweating in the radiotherapy plus goserelin group versus none of 372 patients in the radiotherapy alone group. The most common late adverse events of grade 3 or worse were genitourinary events (29 [8%] in the radiotherapy alone group vs 26 [7%] in the radiotherapy plus goserelin group) and sexual disorders (20 [5%] vs 30 [8%]). No treatment-related deaths occurred.

Interpretation

Adding short-term androgen suppression to salvage radiotherapy benefits men who have had radical prostatectomy and whose PSA rises after a postsurgical period when it is undetectable. Radiotherapy combined with short-term androgen suppression could be considered as a reasonable option in this population.

Funding

French Ministry of Health, AstraZeneca, and La Ligue Contre le Cancer.

Le texte complet de cet article est disponible en PDF.

Plan


© 2016  Elsevier Ltd. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 17 - N° 6

P. 747-756 - juin 2016 Retour au numéro
Article précédent Article précédent
  • Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial
  • Andrea Sartore-Bianchi, Livio Trusolino, Cosimo Martino, Katia Bencardino, Sara Lonardi, Francesca Bergamo, Vittorina Zagonel, Francesco Leone, Ilaria Depetris, Erika Martinelli, Teresa Troiani, Fortunato Ciardiello, Patrizia Racca, Andrea Bertotti, Giulia Siravegna, Valter Torri, Alessio Amatu, Silvia Ghezzi, Giovanna Marrapese, Laura Palmeri, Emanuele Valtorta, Andrea Cassingena, Calogero Lauricella, Angelo Vanzulli, Daniele Regge, Silvio Veronese, Paolo M Comoglio, Alberto Bardelli, Silvia Marsoni, Salvatore Siena
| Article suivant Article suivant
  • Complete lymph node dissection versus no dissection in patients with sentinel lymph node biopsy positive melanoma (DeCOG-SLT): a multicentre, randomised, phase 3 trial
  • Ulrike Leiter, Rudolf Stadler, Cornelia Mauch, Werner Hohenberger, Norbert Brockmeyer, Carola Berking, Cord Sunderkötter, Martin Kaatz, Klaus-Werner Schulte, Percy Lehmann, Thomas Vogt, Jens Ulrich, Rudolf Herbst, Wolfgang Gehring, Jan-Christoph Simon, Ulrike Keim, Peter Martus, Claus Garbe, German Dermatologic Cooperative Oncology Group (DeCOG)

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.


Tout le contenu de ce site: Copyright © 2024 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.